Read on Twitter
NEW—official full trial results of Pfizer/BioNTech vaccine in 43,448 people:
95% efficacy w/ 2 doses
52% efficacy after 1st dose (before 2nd)
10 severe cases, 9 were in placebo
Serious adverse events low & was **similar for vaccine vs placebo**
https://www.nejm.org/doi/full/10.1056/NEJMoa2034577
95% efficacy w/ 2 doses52% efficacy after 1st dose (before 2nd)10 severe cases, 9 were in placeboSerious adverse events low & was **similar for vaccine vs placebo**https://www.nejm.org/doi/full/10.1056/NEJMoa2034577
2) How is the vaccine efficacy across age, gender, race, and country subgroups? Very similar!
3) Technically, the 52% dose 1 efficacy comes from days 0-21. But if we zoom in on the early day, and just look at the efficacy starting around day 10, the efficacy from days 10-21 are likely higher if we exclude the early immunity-building time. So what if just 1 dose many ask?
4) this 1-dose is good question. @ScottGottliebMD thinks that if we have 40 million doses, we shouldn’t withhold half, but that we should just roll out 35 mil for everyone now.
@ArthurCaplan also agrees. We should 1-dose vaccinate as many as possible.
https://amp.usatoday.com/amp/3860363001
@ArthurCaplan also agrees. We should 1-dose vaccinate as many as possible.
https://amp.usatoday.com/amp/3860363001
